GLAND PHARMA
|
GLAND PHARMA Last 5 Year Balance Sheet History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|
EQUITY AND LIABILITIES | ||||
Share Capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr |
Equity - Authorised | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr |
Equity - Issued | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr |
Equity Paid Up | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr |
Equity Shares Forfeited | - | - | - | - |
Adjustments to Equity | - | - | - | - |
Preference Capital Paid Up | - | - | - | - |
Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
Share Warrants & Outstandings | ₹1.67 Cr | ₹13 Cr | ₹25 Cr | ₹16 Cr |
Total Reserves | ₹7,941 Cr | ₹7,128 Cr | ₹5,861 Cr | ₹3,614 Cr |
Securities Premium | ₹1,928 Cr | ₹1,895 Cr | ₹1,840 Cr | ₹589 Cr |
Capital Reserves | - | - | - | - |
Profit & Loss Account Balance | ₹6,015 Cr | ₹5,234 Cr | ₹4,023 Cr | ₹3,026 Cr |
General Reserves | ₹3.12 Cr | ₹3.12 Cr | ₹3.12 Cr | ₹3.12 Cr |
Other Reserves | ₹-6.35 Cr | ₹-4.91 Cr | ₹-4.45 Cr | ₹-3.58 Cr |
Reserve excluding Revaluation Reserve | ₹7,941 Cr | ₹7,128 Cr | ₹5,861 Cr | ₹3,614 Cr |
Revaluation reserve | - | - | - | - |
Shareholder's Funds | ₹7,959 Cr | ₹7,158 Cr | ₹5,903 Cr | ₹3,646 Cr |
Minority Interest | - | - | - | - |
Long-Term Borrowings | - | - | - | - |
Secured Loans | - | - | - | - |
Non Convertible Debentures | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - |
Packing Credit - Bank | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - |
Term Loans - Banks | - | - | - | - |
Term Loans - Institutions | - | - | - | - |
Other Secured | - | - | - | - |
Unsecured Loans | ₹3.26 Cr | ₹3.82 Cr | ₹3.93 Cr | ₹4.07 Cr |
Fixed Deposits - Public | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - |
Loans - Banks | - | - | - | - |
Loans - Govt. | - | - | - | - |
Loans - Others | - | - | - | - |
Other Unsecured Loan | ₹3.26 Cr | ₹3.82 Cr | ₹3.93 Cr | ₹4.07 Cr |
Deferred Tax Assets / Liabilities | ₹84 Cr | ₹88 Cr | ₹74 Cr | ₹74 Cr |
Deferred Tax Assets | ₹23 Cr | ₹7.65 Cr | ₹6.02 Cr | ₹6.05 Cr |
Deferred Tax Liability | ₹107 Cr | ₹95 Cr | ₹80 Cr | ₹80 Cr |
Other Long Term Liabilities | ₹2.22 Cr | ₹2.39 Cr | ₹2.50 Cr | ₹2.66 Cr |
Long Term Trade Payables | - | - | - | - |
Long Term Provisions | - | - | - | - |
Total Non-Current Liabilities | ₹90 Cr | ₹94 Cr | ₹80 Cr | ₹81 Cr |
Current Liabilities | - | - | - | - |
Trade Payables | ₹587 Cr | ₹463 Cr | ₹396 Cr | ₹249 Cr |
Sundry Creditors | ₹587 Cr | ₹463 Cr | ₹396 Cr | ₹249 Cr |
Acceptances | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - |
Other Current Liabilities | ₹109 Cr | ₹76 Cr | ₹62 Cr | ₹82 Cr |
Bank Overdraft / Short term credit | - | - | - | - |
Advances received from customers | ₹76 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr |
Interest Accrued But Not Due | - | - | - | - |
Share Application Money | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - |
Current maturity - Others | - | - | - | - |
Other Liabilities | ₹33 Cr | ₹43 Cr | ₹28 Cr | ₹47 Cr |
Short Term Borrowings | - | - | - | - |
Secured ST Loans repayable on Demands | - | - | - | - |
Working Capital Loans- Sec | - | - | - | - |
Buyers Credits - Unsec | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - |
Other Unsecured Loans | - | - | - | - |
Short Term Provisions | ₹32 Cr | ₹43 Cr | ₹54 Cr | ₹28 Cr |
Proposed Equity Dividend | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - |
Provision for Tax | ₹0.99 Cr | ₹18 Cr | ₹29 Cr | ₹11 Cr |
Provision for post retirement benefits | - | - | - | - |
Preference Dividend | - | - | - | - |
Other Provisions | ₹31 Cr | ₹25 Cr | ₹25 Cr | ₹17 Cr |
Total Current Liabilities | ₹729 Cr | ₹582 Cr | ₹513 Cr | ₹359 Cr |
Total Liabilities | ₹8,778 Cr | ₹7,834 Cr | ₹6,496 Cr | ₹4,086 Cr |
ASSETS | ||||
Gross Block | ₹2,295 Cr | ₹2,081 Cr | ₹1,431 Cr | ₹1,348 Cr |
Less: Accumulated Depreciation | ₹724 Cr | ₹579 Cr | ₹476 Cr | ₹380 Cr |
Less: Impairment of Assets | - | - | - | - |
Net Block | ₹1,571 Cr | ₹1,502 Cr | ₹954 Cr | ₹968 Cr |
Lease Adjustment A/c | - | - | - | - |
Capital Work in Progress | ₹177 Cr | ₹181 Cr | ₹338 Cr | ₹188 Cr |
Non Current Investments | - | - | - | - |
Long Term Investment | - | - | - | - |
Quoted | - | - | - | - |
Unquoted | - | - | - | - |
Long Term Loans & Advances | ₹129 Cr | ₹286 Cr | ₹78 Cr | ₹82 Cr |
Other Non Current Assets | - | ₹2.21 Cr | ₹2.43 Cr | ₹1.66 Cr |
Total Non-Current Assets | ₹1,877 Cr | ₹1,982 Cr | ₹1,372 Cr | ₹1,240 Cr |
Current Assets Loans & Advances | - | - | - | - |
Currents Investments | - | ₹155 Cr | - | - |
Quoted | - | - | - | - |
Unquoted | - | ₹155 Cr | - | - |
Inventories | ₹1,945 Cr | ₹1,186 Cr | ₹1,275 Cr | ₹756 Cr |
Raw Materials | ₹979 Cr | ₹466 Cr | ₹530 Cr | ₹302 Cr |
Work-in Progress | ₹461 Cr | ₹444 Cr | ₹364 Cr | ₹198 Cr |
Finished Goods | ₹82 Cr | ₹46 Cr | ₹170 Cr | ₹64 Cr |
Packing Materials | ₹361 Cr | ₹176 Cr | ₹172 Cr | ₹156 Cr |
Stores Ā and Spare | ₹41 Cr | ₹39 Cr | ₹33 Cr | ₹30 Cr |
Other Inventory | ₹20 Cr | ₹15 Cr | ₹6.33 Cr | ₹6.52 Cr |
Sundry Debtors | ₹871 Cr | ₹1,075 Cr | ₹671 Cr | ₹602 Cr |
Debtors more than Six months | ₹17 Cr | ₹12 Cr | ₹111 Cr | - |
Debtors Others | ₹913 Cr | ₹1,068 Cr | ₹561 Cr | ₹607 Cr |
Cash and Bank | ₹3,771 Cr | ₹3,093 Cr | ₹3,006 Cr | ₹1,325 Cr |
Cash in hand | ₹0.01 Cr | ₹0.02 Cr | ₹0.02 Cr | ₹0.07 Cr |
Balances at Bank | ₹3,771 Cr | ₹3,093 Cr | ₹3,006 Cr | ₹1,325 Cr |
Other cash and bank balances | - | - | - | - |
Other Current Assets | ₹91 Cr | ₹97 Cr | ₹84 Cr | ₹71 Cr |
Interest accrued on Investments | ₹66 Cr | ₹47 Cr | ₹39 Cr | ₹15 Cr |
Interest accrued on Debentures | - | - | - | - |
Deposits with Government | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - |
Prepaid Expenses | ₹14 Cr | ₹14 Cr | ₹11 Cr | ₹9.12 Cr |
Other current_assets | ₹12 Cr | ₹36 Cr | ₹34 Cr | ₹47 Cr |
Short Term Loans and Advances | ₹222 Cr | ₹247 Cr | ₹88 Cr | ₹92 Cr |
Advances recoverable in cash or in kind | ₹120 Cr | ₹178 Cr | ₹13 Cr | ₹15 Cr |
Advance income tax and TDS | - | - | - | ₹9.54 Cr |
Amounts due from directors | - | - | - | - |
Due From Subsidiaries | - | - | - | - |
Inter corporate deposits | - | - | - | - |
Corporate Deposits | - | - | - | - |
Other Loans & Advances | ₹102 Cr | ₹68 Cr | ₹75 Cr | ₹67 Cr |
Total Current Assets | ₹6,901 Cr | ₹5,852 Cr | ₹5,124 Cr | ₹2,846 Cr |
Net Current Assets (Including Current Investments) | ₹6,172 Cr | ₹5,270 Cr | ₹4,611 Cr | ₹2,487 Cr |
Miscellaneous Expenses not written off | - | - | - | - |
Total Assets | ₹8,778 Cr | ₹7,834 Cr | ₹6,496 Cr | ₹4,086 Cr |
Contingent Liabilities | ₹22 Cr | ₹13 Cr | ₹75 Cr | ₹12 Cr |
Total Debt | ₹3.82 Cr | ₹3.93 Cr | ₹4.07 Cr | ₹4.96 Cr |
Book Value | 483.12 | 434.84 | 359.30 | 234.25 |
Adjusted Book Value | 483.12 | 434.84 | 359.30 | 234.25 |
Compare Balance Sheet of peers of GLAND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAND PHARMA | ₹28,945.2 Cr | 0.8% | -3.9% | 45.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
CIPLA | ₹113,471.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹101,960.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics |
GLAND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | 0.8% |
-3.9% |
45.7% |
SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses